TY - JOUR T1 - CAPICE: a computational method for Consequence-Agnostic Pathogenicity Interpretation of Clinical Exome variations JF - medRxiv DO - 10.1101/19012229 SP - 19012229 AU - Shuang Li AU - K. Joeri van der Velde AU - Dick de Ridder AU - Aalt D.J. van Dijk AU - Dimitrios Soudis AU - Leslie R. Zwerwer AU - Patrick Deelen AU - Dennis Hendriksen AU - Bart Charbon AU - Marielle van Gijn AU - Kristin M. Abbott AU - B. Sikkema-Raddatz AU - Cleo C. van Diemen AU - Wilhelmina S. Kerstjens-Frederikse AU - Richard J. Sinke AU - Morris A. Swertz Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/11/29/19012229.abstract N2 - Exome sequencing is now mainstream in clinical practice, however, identification of pathogenic Mendelian variants remains time consuming, partly because limited accuracy of current computational prediction methods leaves much manual classification. Here we introduce CAPICE, a new machine-learning based method for prioritizing pathogenic variants, including SNVs and short InDels, that outperforms best general (CADD, GAVIN) and consequence-type-specific (REVEL, ClinPred) computational prediction methods, for both rare and ultra-rare variants. CAPICE is easily integrated into diagnostic pipelines and is available as free and open source command-line software, file of pre-computed scores, and as a web application with web service API.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the Netherlands Organisation for Scientific Research NWO under VIDI grant number 917.164.455.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCAPICE is available as a free and open source software command-line tool from https://github.com/molgenis/capice and as a web-app at https://molgenis43.gcc.rug.nl/. Pre-computed scores are available as a download at https://doi.org/10.5281/zenodo.3516248 ER -